Biosimilar Market Size, Share, Demand, Report, Forecast 2024-2032

1
Global Biosimilar Market Research and Forecast
Report 2024-2032

• Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group

• IMARC Group is a global management consulting
  firm that helps the worlds most ambitious
  changemakers to create a lasting impact. Across
  the six major continents and 100 countries, we
  work alongside our business partners as one team
  with a common ambition to achieve unparallelled
  results, gain a competitive edge, and transform
  industries. IMARC Group excels in understanding
  its clients business priorities and delivering
  tailored solutions that drive meaningful
  outcomes. Our client base spans over 3,000
  organizations in the private, public, and social
  sectors, ranging from high-growth startups to
  Fortune 500 companies.
• We provide a comprehensive suite of market entry
  and expansion services. Our offerings include
  thorough market assessment, feasibility studies,
  company incorporation assistance, factory setup
  support, regulatory approvals and licensing
  navigation, branding, marketing and sales
  strategies, competitive landscape and
  benchmarking analyses, pricing and cost research,
  and procurement research. These services are
  designed to assist companies in evaluating market
  opportunities, setting up new entities,
  navigating regulatory landscapes, boosting brand
  visibility, analyzing competitors, and optimizing
  procurement strategies.

3
Report Highlight and Description

• According to the latest report by IMARC Group,
  titled "Biosimilar Market Industry Trends,
  Share, Size, Growth, Opportunity and Forecast
  2024-2032," The global biosimilar market size
  reached US 21.2 Billion in 2023.
• Biosimilars, also known as subsequent entry
  biologics (SEBs) or follow-on biologics, refer to
  FDA-approved biotherapeutic products which are
  similar to their reference biologics. Biosimilars
  can only be manufactured after the patent of the
  reference product expires. The demand for
  biosimilars has been increasing in recent years
  as they help in reducing the overall cost of the
  treatment for a variety of chronic diseases
  including cancers, autoimmune diseases, kidney
  failure, diabetes, CVDs, haematological
  disorders, infectious diseases, rheumatoid
  arthritis, growth hormone deficiency, etc.
• Looking forward, IMARC Group expects the market
  to reach US 164.5 Billion by 2032, exhibiting a
  growth rate (CAGR) of 25.1 during 2024-2032.
• Request for a PDF sample of this report
• https//www.imarcgroup.com/biosimilar-market/reque
  stsample

4
Report Description

• Global Biosimilar Market Trends
• Recent patent expiries of a large number of
  blockbuster biological drugs such as Humira,
  Remicade, MabThera, Enbrel, etc. have majorly
  boosted the growth of the biosimilar market.
  Another major growth-inducing factor is ageing
  population which has led to a rise in the
  prevalence of non-communicable diseases. Further,
  high costs of innovator biologics, especially
  monoclonal antibodies (mAbs), have encouraged
  several governments across the globe to promote
  the usage of biosimilars. For instance, European
  countries like the Netherlands, Denmark and
  Germany have established strategic models for
  discount pricing and introduced numerous
  incentive programs.
• Apart from this, biosimilars do not require
  extensive marketing as the safety and efficacy
  profile of biologics has already been
  established. This has resulted into the low cost
  of these drugs in comparison to their branded
  counterparts, in turn, spurring their demand
  worldwide.
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/biosimilar-market

5
Report Segmentation

• Breakup by Molecule
• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab
• Pegfilgrastim
• Trastuzumab
• Bevacizumab
• Others

6
Report Segmentation

• Breakup by Indication
• Auto-Immune Diseases
• Blood Disorder
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility
• Others
• Breakup by Manufacturing Type
• In-house Manufacturing
• Contract Manufacturing

7
Report Segmentation

• Breakup by Region
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Rest of Europe
• United States
• Japan
• India
• South Korea
• Others

8
Competitive Landscape

• Sandoz International GmbH
• Pfizer Inc.
• Teva Pharmaceutical Industries Limited 
• Celltrion Inc. 
• Biocon Limited
• Samsung Biologics 
• Amgen, Inc.
• Dr. Reddy's Laboratories Limited
• Stada Arzneimittel Ag

9
Key Questions Answered in the Report
10
Key Questions Answered in the Report
11
Table of Contents
1 Preface 2 Scope and Methodology 2.1
Objectives of the Study 2.2 Stakeholders
2.3 Data Sources 2.3.1 Primary
Sources 2.3.2 Secondary Sources
2.4 Market Estimation 2.4.1
Bottom-Up Approach 2.4.2 Top-Down
Approach 2.5 Forecasting Methodology 3
Executive Summary 4 Biosimilar Market
Introduction 4.1 Overview 4.2 WHO
and FDA Terminology on Biosimilars 4.3
Biosimilars and Generics 4.4 Biosimilars
and Branded Biological Products 5 Why are
Biosimilars So Lucrative? 5.1 Patent
Expiry of Blockbuster Biological Drugs 5.2
Significant Price Differential between
Biosimilars and Innovator Drugs 5.3
Savings for the Government and Third Party
Payers 5.4 Rising Prevalence of Lifestyle
Diseases 5.5 Incentives for Prescribers,
Pharmacists and Patients 5.6 Emergence of
New Players in Europe and Emerging Markets
5.7 Increasing Product Differentiation as
Manufacturers Tie-Up with Drug Delivery Device
Companies 6 Biosimilar Research, Development
and Manufacturing
12
Table of Contents
6.1 Research and Development Biosimilars
vs. Innovator Drugs 6.2 Manufacturing
Biosimilars vs. Innovator Drugs 7 Global
Biosimilar Market 7.1 Market Overview
7.2 Historical Performance 7.3 Impact
of COVID-19 7.4 Market Breakup by Segment
7.5 Market Breakup by Manufacturing Type
7.6 Market Breakup by Indication 7.7
Market Breakup by Region 7.8 Market
Forecast 7.9 Biosimilar Patent Landscape
7.9.1 Patent Landscape in the US
7.9.2 Patent Landscape in Europe 7.9.3
Patent Landscape in Japan 7.10 SWOT
Analysis 7.10.1 Overview 7.10.2
Strengths 7.10.3 Weaknesses
7.10.4 Opportunities 7.10.5 Threats
7.11 Value Chain Analysis 7.11.1
Characterizing the Existing Innovator Drug
7.11.2 Research and Development
7.11.2.1 Characterization of Biosimilars
7.11.2.2 Developing a Unique Cell Line
7.11.3 Product Development 7.11.3.1
Pre-Testing 7.11.3.2 Intermediary
Clinical Testing (PK/PD) 7.11.3.3
Confirmatory Clinical Phase-III 7.11.4
Final Product Formulation
13
Table of Contents
7.11.5 Marketing and Distribution 7.12
Porters Five Forces Analysis 7.12.1
Overview 7.12.2 Bargaining Power of
Buyers 7.12.3 Bargaining Power of
Suppliers 7.12.4 Degree of Competition
7.12.5 Threat of New Entrants 7.12.6
Threat of Substitutes 7.13 Price Analysis
7.13.1 Key Price Indicators 7.13.2
Price Trends 7.13.3 Margin Analysis 8
Market Breakup by Molecule 8.1 Infliximab
8.2 Insulin Glargine 8.3 Epoetin
Alfa 8.4 Etanercept 8.5 Filgrastim
8.6 Somatropin 8.7 Rituximab 8.8
Follitropin Alfa 8.9 Adalimumab
8.10 Pegfilgrastim 8.11 Trastuzumab
8.12 Bevacizumab 8.13 Others 9 Market
Breakup by Manufacturing Type 9.1 In-house
Manufacturing 9.1.1 Market Trends
9.1.2 Market Forecast 9.2 Contract
Manufacturing
14
Table of Contents
9.2.1 Market Trends 9.2.2 Market
Forecast 10 Market Breakup by Indication
10.1 Auto-Immune Diseases 10.1.1
Market Trends 10.1.2 Market Forecast
10.2 Blood Disorder 10.2.1 Market
Trends 10.2.2 Market Forecast 10.3
Diabetes 10.3.1 Market Trends
10.3.2 Market Forecast 10.4 Oncology
10.4.1 Market Trends 10.4.2 Market
Forecast 10.5 Growth Deficiency
10.5.1 Market Trends 10.5.2 Market
Forecast 10.6 Female Infertility
10.6.1 Market Trends 10.6.2 Market
Forecast 10.7 Others 10.7.1 Market
Trends 10.7.2 Market Forecast 11 Market
Breakup by Region 11.1 Europe
11.1.1 Market Performance 11.1.2 Key
Players and Biosimilars 11.1.3 Market
Breakup by Country 11.1.4 Market
Forecast 11.1.5 Italy
11.1.5.1 Market Performance
15
Table of Contents
11.1.5.2 Key Players and Biosimilars
11.1.5.3 Market Forecast
11.1.6 Germany 11.1.6.1 Market
Performance 11.1.6.2 Key Players and
Biosimilars 11.1.6.3 Market Forecast
11.1.7 France 11.1.7.1 Market
Performance 11.1.7.2 Key Players and
Biosimilars 11.1.7.3 Market Forecast
11.1.8 United Kingdom 11.1.8.1
Market Performance 11.1.8.2 Key
Players and Biosimilars 11.1.8.3
Market Forecast 11.1.9 Spain
11.1.9.1 Market Performance 11.1.9.2
Key Players and Biosimilars 11.1.9.3
Market Forecast 11.1.10 Rest of Europe
11.1.10.1 Market Performance
11.1.10.2 Market Forecast 11.2 United
States 11.2.1 Current Market Trends
11.2.2 Key Players and Biosimilars
11.2.3 Market Forecast 11.3 Japan
11.3.1 Market Performance 11.3.2 Key
Players and Biosimilars 11.3.3 Market
Forecast 11.4 India 11.4.1 Current
Market Trends 11.4.2 Key Players and
Biosimilars
16
Table of Contents
11.4.3 Market Forecast 11.5 South
Korea 11.5.1 Current Market Trends
11.5.2 Key Players and Biosimilars
11.5.3 Market Forecast 11.6 Rest of the
World 11.6.1 Current Market Trends
11.6.2 Market Forecast 12 Requirements for
Setting Up a Biosimilar Manufacturing Plant
12.1 Manufacturing Process 12.2 Raw
Material Requirements 12.3 Raw Material
Pictures 12.4 Land and Construction
Requirements 12.5 Machinery and
Infrastructure Requirements 12.6 Machinery
Pictures 12.7 Plant Layout 12.8
Packaging Requirements 12.9 Utility
Requirements 12.10 Manpower
Requirements 13 Competitive Landscape 13.1
Market Structure 13.2 Key Players
13.3 Profiles of Key Players 13.3.1
Sandoz International GmbH 13.3.2
Pfizer Inc. 13.3.3 Teva Pharmaceutical
Industries Limited 13.3.4 Celltrion
Inc. 13.3.5 Biocon Limited
13.3.6 Samsung Biologics 13.3.7
Amgen, Inc. 13.3.8 Dr. Reddy's
Laboratories Limited
17
Table of Contents
13.3.9 Stada Arzneimittel Ag For more
information, visit https//www.imarcgroup.com/bio
similar-market/toc
18
Partial List of Clients
19
Partial List of Clients
20
Disclaimer

• 2024 IMARC All Rights Reserved
• This Publication and all its contents unless
  otherwise mentioned are copyrighted in the name
  of International Market Analysis Research and
  Consulting (IMARC). No part of this publication
  may be reproduced, repackaged, redistributed or
  resold in whole or in any part. The publication
  may also not be used in any form or by and means
  graphic electronic or mechanical, including
  photocopying, recording, taping or by information
  storage or retrieval, or by any other form,
  without the express consent of International
  Market Analysis Research and Consulting (IMARC).
• Disclaimer All contents and data of this
  publication, including forecasts, data analysis
  and opinion have been based on information and
  sources believed to be accurate and reliable at
  the time of publishing. International Market
  Analysis Research and Consulting makes no
  representation of warranty of any kind as to the
  accuracy or completeness of any Information
  provided. IMARC accepts no liability whatsoever
  for any loss or damage resulting from opinion,
  errors or inaccuracies if any found this
  publication.
• IMARC, IMARC Group and Global Therapy Insight
  Series are registered trademarks of International
  Market Analysis Research and Consulting. All
  other trademarks used in this publication are
  registered trademarks of their respective
  companies.

21
Contact Us
Visit us at
https//www.imarcgroup.com
1-631-791-1145
sales_at_imarcgroup.com
Stay With Us